Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2008 Target Snapshot

Retinoic acid receptor beta · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
715Compounds
254Assays
17Approved Drugs
690.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Retinoic acid receptor beta shows late clinical disease relevance led by myelodysplastic syndrome. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P10826. Start with myelodysplastic syndrome, then reuse UniProt P10826 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with myelodysplastic syndrome, then reuse UniProt P10826 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
myelodysplastic syndrome

Retinoic acid receptor beta shows late clinical disease relevance led by myelodysplastic syndrome. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with myelodysplastic syndrome because it currently carries late clinical support. Linked drugs include TAMIBAROTENE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Late clinical Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Retinoic acid receptor beta as ChEMBL target CHEMBL2008, mapped to UniProt P10826. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Retinoic acid receptor beta
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2008
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P10826
Retinoic acid receptor beta
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Retinoic acid receptor beta is the right protein anchor across sources, using UniProt P10826 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why myelodysplastic syndrome is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameRetinoic acid receptor beta
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP10826
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelRetinoic acid receptor beta
UniProt AccessionP10826
Component TypeProtein
Sequence Length455 aa

Retinoic acid receptor beta

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Retinoic acid receptor beta, mapped to UniProt P10826. Sequence length is 455 aa.

Mapped IDP10826
Review nameRetinoic acid receptor beta
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

Retinoic acid receptor beta shows late clinical disease relevance led by myelodysplastic syndrome. 5 more disease programs remain visible in the same review block.

Late clinical Phase III
myelodysplastic syndrome
1 linked drug · 1 direct · 1 efficacy
Linked drugTAMIBAROTENE
Clinical signal Phase II
acute myeloid leukemia
1 linked drug · 1 direct · 1 efficacy
Linked drugTAMIBAROTENE
Clinical signal Phase II
acute promyelocytic leukemia
1 linked drug · 1 direct · 1 efficacy
Linked drugTAMIBAROTENE
Clinical signal Phase II
Alzheimer disease
1 linked drug · 1 direct · 1 efficacy
Linked drugTAMIBAROTENE
Clinical signal Phase II
Autosomal dominant polycystic kidney disease
1 linked drug · 1 direct · 1 efficacy
Linked drugTAMIBAROTENE
Clinical signal Phase II
Crohn's disease
1 linked drug · 1 direct · 1 efficacy
Linked drugTAMIBAROTENE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with myelodysplastic syndrome because it currently carries late clinical support. Linked drugs include TAMIBAROTENE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasemyelodysplastic syndrome
Strongest levelLate clinical
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

17
Approved
1
Phase II
Assay Mix

Activity Type Distribution

IC5070.0
KI123.0
EC50354.0
KD143.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL451835 9.52 EC50 0.3 Preclinical
CHEMBL5997757 9.52 EC50 0.3 Preclinical
CHEMBL12585 9.4 EC50 0.4 Preclinical
CHEMBL441231 9.4 EC50 0.4 Preclinical
CHEMBL38 9.4 Ki 0.4 Approved
CHEMBL38 9.4 Kd 0.4 Approved
CHEMBL285179 9.3 EC50 0.5 Preclinical
CHEMBL275311 9.3 Ki 0.5 Preclinical
CHEMBL705 9.3 Ki 0.5 Approved
CHEMBL89241 9.15 Ki 0.7 Preclinical
Distribution

pChEMBL Value Distribution

25
5.0
34
5.5
41
6.0
59
6.5
82
7.0
101
7.5
81
8.0
35
8.5
18
9.0
2
9.5
pChEMBL
Approved Drugs

Approved Drugs

TRIFAROTENE
CHEMBL3707313
Approved 2019
Properties Compare Identifier
TAMIBAROTENE
CHEMBL25202
Approved 2005
Properties Compare Identifier
ALITRETINOIN
CHEMBL705
Approved 1999
Properties Compare Identifier
BEXAROTENE
CHEMBL1023
Approved 1999
Properties Compare Identifier
TAZAROTENE
CHEMBL1657
Approved 1997
Properties Compare Identifier
ADAPALENE
CHEMBL1265
Approved 1996
Properties Compare Identifier
TRETINOIN
CHEMBL38
Approved 1971
Properties Compare Identifier
Assay Landscape

Assay Landscape

255
Total Assays
300
Tested Compounds
3
Assay Types
Binding — 177 assays, 300 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 108 144 7.3
cell-based format 69 156 7.3
Functional — 77 assays, 74 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 50 43 7.2
assay format 27 31 7.5
ADME — 1 assays, 3 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 1 3 6.5

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine